March 11-15 | Saarbrücken, Germany
Wednesday, Health & Pharmaceutic applications: Mathieu Gaudin, ImaBiotech, Lille, France: Morphological Analysis of Mass Spectrometry Imaging Data to Discover Heterogeneity Markers in Oncology
About Dr. Gaudin, Lab Manager
After having obtained his Chemical Engineering degree during is Ph.D. at aris Descartes University (France), he developed untargeted and semi-targeted mass spectrometry-based approaches for lipidomic characterization of brain tissue samples by liquid chromatography mass spectrometry to understand better the physiopathology of Alzheimer’s disease. After four years at Servier where he contributed to the drug distribution strategy and managed the Mass Spectrometry Imaging facility, he joined our team in 2017 as a laboratory manager of the Europe facility.
ImaBiotech supports pharmaceutical industry with innovative Imaging services that predict more accurately which treatment will work in stratified population.
ImaBiotech is a Contract Research Organization (CRO) with two facilities one in Boston (MA) and one in France. The company offers innovative services to the pharmaceutical research to provide better drug efficacy and toxicity evaluations from preclinical to clinical stages, making better and safer drugs.
Services are based on different imaging techniques combined to Quantitative Mass Spectrometry a technology developed and constantly improved by ImaBiotech. Quantitative Mass Spectrometry (QMSI) has been developed for decades and allows to detect elements and molecules without labelling. ImaBiotech has developed the quantitative aspects through many patents making ImaBiotech the worldwide leader in this field. QMSI is a game changer of the pharmaceutical industry in all therapeutic areas. While actual techniques provide global information, this molecular technique brings deeper information about drug localization and its pharmacology effects to recover disease tissues and damaged cells. This increases the interpretation of drug efficacy and toxicity improving drugs and improving time to market. To interpret datas we’ve developed, thanks to our patents, two softwares called Quantinetix and Multimaging to interpret pharmacology in tissue.